Full Title
Lurbinectedin in FET-Fused Tumors (CHOP IRB)Purpose
Researchers in this study want to find the best dose of lurbinectedin to treat cancer in children and adults. They also want to see how well this drug works. The people in this study have Ewing sarcoma or other solid tumors that keep growing after treatment. In addition, their cancers contain a genetic change called a FET fusion.
A FET fusion includes the “FET” genes FUS, EWSRI, or TAF15. It may be seen in people with:
- Ewing sarcoma
- Desmoplastic small round cell tumor
- Clear cell sarcoma
- Myxoid liposarcoma
- Myxoid chondrosarcoma
- Sclerosing epithelioid fibrosarcoma
- Angiomatoid fibrous histiocytoma
- Myoepithelioma
Lurbinectedin is a type of drug called an alkylating agent. These drugs target cancer cells and interfere with their DNA (genetic material) to slow or stop cell growth. Lurbinectedin is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have Ewing sarcoma or another solid tumor that came back or keeps growing after treatment.
- Have cancer that contains a FET fusion.
- Have recovered from the serious side effects of prior anti-cancer therapies before getting lurbinectedin.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 10 or older.
Contact
For more information and to see if you or your child can join this study, please call 833-MSK-KIDS.